MNKD · XBRL financial data

MannKind financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MNKD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	65	75	100	199	286	349
Cost of goods and services sold	15	17	16	21	17	27
Selling, general and administrative	59	77	91	94	94	144
General and administrative	25	32	38	43	—	—
Total operating expenses	25	39	57	63	77	88
Operating income (loss)	(48)	(47)	(64)	9	73	39
Interest income	0	0	3	6	13	8
Interest expense	4	15	10	15	12	14
Other income (expense)	0	(0)	(0)	0	0	(1)
Income tax expense (benefit)	(0)	0	0	2	3	(4)
Net income (loss)	(57)	(81)	(87)	(12)	28	6
Earnings per share, basic USD per share	(0.26)	(0.32)	(0.34)	(0.04)	0.10	0.02
Earnings per share, diluted USD per share	(0.26)	(0.32)	(0.34)	(0.04)	0.10	0.02
Weighted average shares, basic millions of shares	223	249	257	267	274	306
Weighted average shares, diluted millions of shares	223	249	257	267	284	314

Fiscal years (MNKD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	67	124	70	238	46	75
Short-term investments	0	80	101	57	151	96
Accounts receivable	4	5	17	15	12	38
Inventory	5	7	22	29	28	35
Prepaid and other current assets	3	3	25	35	31	47
Total current assets	79	220	235	373	268	292
Property and equipment, net	26	37	45	84	85	82
Right-of-use asset	—	2	7	5	13	12
Goodwill	—	—	2	2	2	68
Total assets	109	321	295	475	394	792
Accounts payable	6	7	11	10	7	9
Accrued liabilities	20	27	36	42	40	65
Total current liabilities	74	48	67	104	82	171
Lease liability, non-current	1	1	5	4	12	11
Total liabilities	289	531	546	721	473	843
Accumulated deficit	(3,049)	(3,130)	(3,217)	(3,229)	(3,202)	(3,196)
Total stockholders' equity	(180)	(209)	(251)	(246)	(79)	(51)
Total liabilities and equity	109	321	295	475	394	792
Common shares outstanding (cover page) millions of shares	247	252	264	270	304	308

Fiscal years (MNKD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(57)	(81)	(87)	(12)	28	6
Stock-based compensation	7	12	13	18	21	24
Net cash from operating activities	(28)	(62)	(81)	34	43	18
Purchases of property and equipment	1	11	8	42	10	5
Net cash from investing activities	15	(152)	5	(2)	(97)	(305)
Proceeds from long-term debt	5	—	—	—	—	—
Net cash from financing activities	50	270	21	137	(137)	315
Net change in cash	37	57	(54)	169	(191)	29

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Mannkind	53	109	(18)*	321.5M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Schrodinger	288	59	(34)*	not reported	12.1 quarters	Q2 FY26 10-QJun 30, 2026
Spyre Therapeutics	83	not reported	(77)*	95.0M	15.7 quarters	Q3 FY26 10-QSep 30, 2026
Novavax	191	57	(73)*	164.9M	9.9 quarters	Q2 FY26 10-QJun 30, 2026
Innoviva	570	120	52*	72.2M	—	Q2 FY26 10-QJun 30, 2026
Harrow	84	71	(9.8)*	37.5M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Aurinia Pharmaceuticals	46	84	46*	134.0M	—	Q3 FY26 10-QSep 30, 2026
Ani Pharmaceuticals	360	266	57*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47	0	(57)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.